Serum (1→3)-β-D-glucan and galactomannan levels in patients with cystic fibrosis: a retrospective cohort study
Open accessAbstract
BACKGROUND: Aspergillus fumigatus is frequently encountered in sputum samples of patients with cystic fibrosis (CF), which traditionally has been interpreted as saprophytic airway colonization. However, this mere bystander role has been challenged by recent data. There is now evidence that Aspergillus fumigatus accelerates the decline of pulmonary function. (1→3)-β-D-glucan (BDG) and galactomannan (GM) are highly sensitive fungal biomarkers that are used to diagnose invasive fungal disease. However, their diagnostic value in CF patients is largely unknown. METHODS: We conducted a retrospective cohort study on 104 CF patients to determine whether serum BDG and GM levels correlate with parameters such as Aspergillus-positive sputum cultures and lung function. RESULTS: Aspergillus fumigatus was persistently detected in 22 of the 104 CF patients (21%). Mean serum BDG and GM levels in the Aspergillus-positive patients were significantly higher than in those without persistent Aspergillus detection (89 versus 40 pg/ml [p = 0.022] and 0.30 versus 0.15 ODI [p = 0.013], respectively). 27 and 7 patients had elevated BDG (≥ 60 pg/ml) or GM levels (> 0.5 ODI), respectivly. BDG and GM levels showed a significant correlation (p = 0.004). Patients with increased serum concentrations of BDG were more frequently Aspergillus-positive (40.7 versus 14.3%, p = 0.004) and had a significantly lower forced expiratory volume in one second (FEV1) than patients with a normal BDG (61.6 versus 77.1%, p = 0.007). In the multivariate analysis, BDG but not GM or the growth of A. fumigatus, proved to be an independent predictor for the FEV1. CONCLUSIONS: CF patients with persistent Aspergillus detection have elevated BDG and GM levels which ranged between healthy and invasively infected patients. Serum BDG may be superior to GM and fungal culture in predicting an impaired lung function in CF patients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Recent studies showed that BAL fluid GM has improved sensitivity compared to serum GM in high-risk patients with IPA, including nonneutropenic patients.
“Recent studies showed that BAL fluid GM has improved sensitivity compared to serum GM in high-risk patients with IPA, including nonneutropenic patients (88, 114–119).”
From Aspergillus fumigatus and Aspergillosis in 2019 (2019) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771 · see citing works
Webb, A. K. (2006) · Cited by 4,369 · see citing works
Rowe, S. M., Miller, S., & Sorscher, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043184 · Cited by 1,398 · see citing works
Lee, T. W. R., Brownlee, K. G., Conway, S. P., Denton, M., & Littlewood, J. M. (2003) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(02)00141-8 · Cited by 714 · see citing works
Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis
Mennink‐Kersten, M. A. S. H., Donnelly, J. P., & Verweij, P. E. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01045-x · Cited by 482 · see citing works
Microbiology of Sputum from Patients at Cystic Fibrosis Centers in the United States
Burns, J. L., Emerson, J., Stapp, J. R., Yim, D. L., Krzewinski, J., Louden, L., Ramsey, B. W., & Clausen, C. R. (1998) · Clinical Infectious Diseases · doi:10.1086/514631 · Cited by 420 · see citing works
Amin, R., Dupuis, A., Aaron, S. D., & Ratjen, F. A. (2009) · CHEST Journal · doi:10.1378/chest.09-1103 · Cited by 375 · see citing works
Pihet, M., Carrère, J., Cimon, B., Chabasse, D., Delhaes, L., Symoens, F., & Bouchara, J. (2009) · Medical Mycology · doi:10.1080/13693780802609604 · Cited by 315 · see citing works
Kanda, T., Fujii, H., Tani, T., Murakami, H., Suda, T., Sakai, Y., Ono, T., & Hatakeyama, K. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8566578 · Cited by 283 · see citing works
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
Hodson, M. E., Gallagher, C. G., & Govan, J. R. W. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00248102 · Cited by 269 · see citing works
Aspergillus Bronchitis in Cystic Fibrosis
Shoseyov, D., Brownlee, K. G., Conway, S. P., & Kerem, E. (2006) · CHEST Journal · doi:10.1378/chest.130.1.222 · Cited by 161 · see citing works
Schellekens, D. H. S. M., Grootjans, J., Dello, S. A. W. G., van Bijnen, A. A. J. H. M., van Dam, R. M., Dejong, C. H. C., Derikx, J. P. M., & Buurman, W. A. (2013) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182a87e3e · Cited by 142 · see citing works
Cheer, S. M., Waugh, J., & Noble, S. (2003) · Drugs · doi:10.2165/00003495-200363220-00015 · Cited by 142 · see citing works
Sulahian, A., Porcher, R., Bergeron, A., Touratier, S., Raffoux, E., Ménotti, J., Derouin, F., & Ribaud, P. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.03567-13 · Cited by 124 · see citing works
Schurink, M., Kooi, E. M. W., Hulzebos, C. V., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121336 · Cited by 119 · see citing works
Fungi in the cystic fibrosis lung: Bystanders or pathogens?
Chotirmall, S. H., & McElvaney, N. G. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.03.001 · Cited by 113 · see citing works
Aspergillus fumigatus colonization in cystic fibrosis: implications for lung function?
de Vrankrijker, A. M. M., van der Ent, C. K., van Berkhout, F. T., Stellato, R. K., Willems, R. J. L., Bonten, M. J. M., & Wolfs, T. F. W. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03429.x · Cited by 112 · see citing works
Bargon, J., Dauletbaev, N., Köhler, B., Wolf, M., Posselt, H., & Wagner, T. O. F. (1999) · Respiratory Medicine · doi:10.1016/s0954-6111(99)90270-6 · Cited by 102 · see citing works
Jubin, V., Ranque, S., le Bel, N. S., Sarles, J., & Dubus, J. ‐. (2010) · Pediatric Pulmonology · doi:10.1002/ppul.21240 · Cited by 88 · see citing works
Comparison of techniques to examine the diversity of fungi in adult patients with cystic fibrosis
Nagano, Y., Elborn, J. S., Millar, B. C., Walker, J. M., Goldsmith, C. E., Rendall, J. C., & Moore, J. E. (2010) · Medical Mycology · doi:10.3109/13693780903127506 · Cited by 84 · see citing works
Milla, C. E., Wielinski, C. L., & Regelmann, W. E. (1996) · Pediatric Pulmonology · doi:10.1002/(sici)1099-0496(199601)21:1 · Cited by 81 · see citing works
Intravenous antibiotics reduce the presence ofAspergillusin adult cystic fibrosis sputum
Baxter, C. G., Rautemaa‐Richardson, R., Jones, A. M., Webb, A. K., Bull, M. J., Mahenthiralingam, E., & Denning, D. W. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202412 · Cited by 67 · see citing works
Fillaux, J., Brémont, F., Murris, M., Cassaing, S., Rittié, J. L., Tetu, L., Segonds, C., Abbal, M., Bieth, É., Berry, A., et al. (2012) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2012.695454 · Cited by 66 · see citing works
Pneumocystis jiroveciiinfection: Cell wall (1→3)-β-D-glucan biology and diagnostic utility
Finkelman, M. (2010) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2010.484001 · Cited by 39 · see citing works
Factors effecting impact of Aspergillus fumigatus sensitization in cystic fibrosis
Kanthan, S. K., Bush, A., Kemp, M., et al. (2007) · Pediatric Pulmonology · doi:10.1002/ppul.20656 · Cited by 27 · see citing works
Cai, X., Ni, W., Wei, C., & Cui, J. (2014) · Internal Medicine · doi:10.2169/internalmedicine.53.2381 · Cited by 26 · see citing works
Serum galactomannan in cystic fibrosis patients colonized withAspergillusspecies
Warren, T. A., Yau, Y. C. W., Ratjen, F. A., Tullis, E. D., & Waters, V. J. (2012) · Medical Mycology · doi:10.3109/13693786.2012.676739 · Cited by 16 · see citing works
Rautemaa, V., Green, H. D., Jones, A. M., & Rautemaa‐Richardson, R. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.05.010 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Aspergillus fumigatus and Aspergillosis in 2019
Latgé, J.-P., & Chamilos, G. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-18 · Cited by 1,400 · see citing works
- Authors
- Träger, J., Melichar, V. O., Meyer, R., Rauh, M., Bogdan, C., & Held, J.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Corresponding author
- Held, Jürgen
- Venue
- BMC Pulmonary Medicine
- Published
- 2018-03-27
- Volume
- 18
- Issue
- 1
- Pages
- 52-52
- ISSN
- 1471-2466 (ISSN-L)
- PMC
- PMC5870392
- OpenAlex
- W2801489312
- Cited by
- 7
- References
- 28
- Citations by year
- 2024: 3 · 2022: 1 · 2020: 1 · 2019: 2
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Pulmonary Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OPUS Repository (Kooperativer Bibliotheksverbund Berlin-Brandenburg) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- cystic fibrosis, Aspergillus fumigatus, β-1,3-glucan, galactomannan, fungal biomarkers, invasive fungal infections, lung function decline, FEV1, sputum culture, pulmonary function prediction
- MeSH terms
- Adolescent, Adult, Aspergillus fumigatus, Child, Child, Preschool, Cystic Fibrosis, Female, Forced Expiratory Volume, Galactose, Humans, Male, Mannans, Middle Aged, Proteoglycans, Retrospective Studies, Sputum, Cohort Studies, Multivariate Analysis, Case-Control Studies, Culture Techniques, beta-Glucans, Pulmonary Aspergillosis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
